Association Between CYP17A1, CYB5A Polymorphisms and Efficacy of Abiraterone Acetate/Prednisone Treatment in Castration-Resistant Prostate Cancer Patients.

PURPOSE: The purpose of this study was to investigate the association between single nucleotide polymorphisms (SNPs) of CYP17A1, CYB5A and the efficacy of abiraterone acetate treatment in patients with castration-resistant prostate cancer (CRPC). PATIENTS AND METHODS: Data were collected from 58 CRPC patients who had been treated with abiraterone acetate/prednisone (AA/P). The SNPs rs743572 and rs10883783 on CYP17A1 and SNPs rs1790834 and rs1790858 on CYB5A were assayed, and their relationship with prostate-specific antigen (PSA) response in patients after AA/P treatment, overall survival (OS) and progression-free survival (PFS) were analyzed by logistic regression, Cox regression, Kaplan-Meier and Log rank analyses. RESULTS: The SNP rs1790834 on CYB5A showed significant association with PSA response in CRPC patients treated with AA/P (P < 0.05), but rs743572, rs10883783 and rs1790858 did not. The rs1790834 variant significantly decreased both PFS and OS (P < 0.05). CONCLUSION: The CYB5A rs790834 genotype is a novel SNP related to CRPC and may be used as a biomarker for CRPC treatment.

Risk factors for infectious complications following transrectal ultrasound-guided prostate biopsy.

OBJECTIVE: To explore risk factors of infectious complications following transrectal ultrasound-guided prostate biopsy (TRUSPB). METHODS: We retrospectively analyzed 1,203 patients with suspected prostate cancer who underwent TRUSPB at our center between December 2012 and December 2016. Demographics, clinical characteristics, and data regarding complications were collected, and then univariate and multivariate logistic regression analyses were used to identify independent risk factors for infectious complications after prostate biopsy. RESULTS: Multivariate logistic analysis demonstrated that body mass index (BMI) (OR=2.339, 95% CI 2.029-2.697, P<0.001), history of diabetes (OR=2.203, 95% CI 1.090-4.455, P=0.028), and preoperative catheterization (OR=2.303, 95% CI 1.119-4.737, P=0.023) were risk factors for infection after prostate biopsy. The area under the receiver operating characteristics curve for infectious complications was 0.930 (95% CI 0.907-0.953, P<0.001). BMI=28.196 kg/m2 was the best cut-off threshold for predicting infection after TRUSPB. CONCLUSION: BMI >28.196 kg/m2, history of diabetes, and preoperative catheterization are independent risk factors for infection after prostate biopsy.